Press release
Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board
NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the addition of Dr. Alexander Fleming to its Scientific Advisory Board.\n\n \n \n\n \nDr. Fleming is Founder and Executive Chairman of Kinexum. Dr. Fleming previously held various positions at the U.S. Food and Drug Administration in which he was responsible for the therapeutic areas of diabetes and other metabolic and endocrine disorders. He led reviews of landmark approvals, including metformin and the first statin, insulin analog, PPAR-agonist, and growth hormone for non-GH deficiency indications. Dr. Fleming oversaw clinical review of the earliest biotech products, including human insulin. Dr. Fleming also helped to shape FDA policies and practices related to therapeutic review and regulatory communication. \n\"We are honored and extremely fortunate to welcome Dr. Fleming to our Scientific Advisory Board. His expansive knowledge of diabetes and clinical development will be invaluable as our oral ORMD-0801 insulin program continues to progress towards our vision of becoming the first oral insulin therapy available to physicians and their patients battling diabetes,\" said Nadav Kidron, CEO of Oramed.\nAbout Oramed Pharmaceuticals\nOramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of Type 2 and Type 1 diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.\nFor more information, please visit www.oramed.com.\nForward-looking statements: This press release contains forward-looking statements. For example, we...